WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y Combinator, the company is establishing itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks.

WhiteLab collaborates with major pharmaceutical companies (such as Sanofi), leading academic institutions, and innovative biotech companies. WhiteLab is a member of the prestigious French Tech 2030 program and is part of Bayer Co.Lab in Cambridge (USA).